purpos
experiment
designrecombin
human
potent
cytokin
fdaapprov
anticanc
drug
howev
clinic
use
limit
sever
toxic
associ
primarili
system
administr
excess
protein
distribut
freeli
throughout
bodi
hypothes
altern
form
permit
restrict
local
may
exert
stronger
antitumor
efficaci
less
toxic
test
util
palmitatederivat
react
nhydroxysuccinimid
palmit
ester
result
lipid
mix
cell
could
spontan
transfer
solut
cell
surfac
next
anticanc
efficaci
assess
two
modal
adopt
cell
therapi
antitumor
cytotox
cell
ctl
protein
transfer
paint
inject
mice
bear
lymphoma
situ
therapi
inject
intratumor
mice
bear
melanoma
tumor
growth
toxic
determin
resultsin
lymphoma
model
paint
antitumor
ctl
markedli
increas
viabil
titer
melanoma
model
intratumor
inject
increas
number
activ
cell
spleen
reduc
lung
metastasi
prolong
surviv
treat
mice
moreov
repeat
intratumor
inject
excess
high
dose
inject
iumous
caus
mark
vascular
leakag
syndrom
regimen
use
caus
detect
toxic
conclusionstransf
spontan
solut
cell
surfac
may
bypass
current
limit
thu
serv
effect
toler
anticanc
drug
cytokin
origin
identifi
cell
growth
factor
known
exert
divers
stimulatori
effect
variou
immun
cell
includ
b
cell
natur
killer
nk
cell
monocyt
macrophag
produc
secret
activ
cell
primarili
cell
recombin
human
fdaapprov
protein
drug
metastat
melanoma
renal
cell
carcinoma
also
test
clinic
trial
drug
chronic
viral
infect
adjuv
vaccin
despit
potenti
efficaci
clinic
use
limit
system
toxic
induc
administr
therapeut
dosag
includ
myocardi
infarct
renal
failur
fluid
retent
nausea
neuropathi
gener
inflammatori
chang
capillari
leak
syndrom
toxic
stem
larg
mode
administr
manufactur
solubl
protein
administ
system
iv
therapeut
dosag
well
physiolog
level
larg
excess
protein
distribut
freeli
tissu
throughout
bodi
thu
caus
system
toxic
one
strategi
reduc
toxic
form
block
antibodi
complex
select
block
toxicitycaus
site
altern
strategi
test
report
derivat
form
reduc
free
diffus
protein
show
chemic
lipid
palmit
subsequ
gain
abil
anchor
onto
cell
surfac
via
lipid
chain
thu
surfaceincorpor
immun
modul
palmitatederivat
refer
hereaft
lend
novel
mode
action
may
enhanc
efficaci
minim
diffus
protein
thu
system
toxic
test
hypothesi
two
anticanc
modal
show
paint
therapeut
cytotox
cell
increas
efficaci
adopt
transfer
therapi
also
show
inject
intratumor
strong
antitumor
efficaci
minim
toxic
tcrtransgen
mice
bred
univers
illinoi
colleg
medicin
rockford
anim
facil
inbr
mice
jackson
laboratori
bar
harbor
main
anim
maintain
pathogenfre
facil
use
accord
institut
guidelin
anim
care
lymphoma
melanoma
line
american
type
cultur
collect
manassa
va
maintain
per
supplier
instruct
antibodi
ebiosci
san
diego
ca
iumg
peprotech
nj
derivat
nhydroxysuccinimid
ester
palmit
acid
sigmaaldrichm
st
loui
mo
previous
describ
purifi
sephadex
column
sigmaaldrich
result
quantifi
use
bicinchonin
acid
kit
biorad
richmond
ca
filter
store
use
splenic
cell
isol
mice
neg
select
use
mac
kit
miltenyi
biotec
cell
incub
cell
bsa
min
assess
transfer
onto
cell
surfac
cell
wash
twice
stain
biotinyl
rabbit
ab
apcconjug
streptavidin
analyz
facscalibur
bd
bioscienc
san
jose
ca
splenic
cell
activ
hamster
antimous
platebound
iuml
peprotech
inc
day
amplifi
iuml
anoth
day
cell
harvest
cell
vitro
assay
cell
paint
replat
medium
without
control
cell
cell
nonpaint
replat
medium
neg
control
medium
contain
ng
posit
control
cell
sampl
taken
daili
stain
invitrogen
corp
carlsbad
ca
live
cell
count
flow
cytometri
vivo
assay
cell
divid
label
either
carboxyfluorescein
succinimidyl
ester
cfse
invitrogen
cfselabel
cell
paint
mix
equal
number
cell
intern
control
cell
number
coadopt
transfer
footpad
mice
total
cellsmous
control
paint
nonpaint
cfselabel
cell
mockpaint
cfselabel
cell
similarli
coadopt
transfer
addit
group
mice
three
day
later
total
cellular
content
lymph
node
drain
inject
site
poplit
quantifi
cfse
cell
flow
cytometri
gate
cell
ratio
cfse
cell
cell
determin
winn
assay
cell
perform
describ
previous
day
melanoma
cell
inject
intraderm
mous
back
flank
mice
day
inject
intratumor
palpabl
tumor
ngmous
inject
repeat
daili
total
day
autopsi
perform
day
time
death
earlier
number
metastat
coloni
lung
count
dissect
scope
quantit
vascular
leakag
syndrom
perform
follow
method
describ
mustafa
et
al
twosid
mannwhitney
u
test
use
surviv
analysi
unpair
twosid
student
test
use
pairwis
comparison
differ
consid
signific
p
back
colski
peacock
show
antibodi
chemic
derivat
palmit
ester
could
incorpor
onto
cell
membran
via
insert
palmit
lipid
chain
adapt
approach
past
demonstr
conclus
palmitatederivat
protein
could
readili
transfer
solut
onto
cell
palmit
moietydepend
manner
ex
vivo
incub
cell
vivo
inject
tissu
transfer
protein
remain
cellbound
day
ex
vivo
h
vivo
present
studi
similarli
derivat
palmit
gener
membraneincorpor
form
permit
local
cytokin
onto
cell
use
cell
model
show
incub
cell
solubl
result
transfer
cytokin
onto
cell
surfac
wherea
incub
nonlipid
fail
fig
moreov
cell
without
incub
show
level
cellsurfac
indic
direct
bind
neglig
result
confirm
membraneincorpor
next
evalu
use
cancer
therapi
one
major
util
adopt
cell
therapi
inject
system
patient
prolong
surviv
transfus
therapeut
cell
rais
ex
vivo
thu
becom
vivo
hypothes
directli
paint
onto
cell
may
increas
surviv
bypass
need
system
inject
associ
toxic
test
cell
activ
mab
expand
murin
day
cultur
cell
incub
ng
min
wash
replat
medium
control
nonpaint
cell
replat
medium
medium
contain
ng
posit
control
live
cell
count
daili
flow
cytometri
result
show
nonpaint
cell
die
day
without
respect
fig
contrast
cell
prolifer
day
result
larger
cell
popul
day
baselin
indic
paint
cell
prolong
viabil
ex
vivo
determin
whether
also
case
vivo
cell
adopt
transfer
mice
control
paint
cell
mockpaint
similarli
transfer
control
number
cell
inject
paint
mockpaint
cell
label
green
fluoresc
dye
cfse
transfer
togeth
number
nonpaint
cell
label
red
dye
three
day
later
total
cellular
content
drain
lymph
node
group
analyz
flow
cytometri
shown
fig
number
mockpaint
cell
nonpaint
cell
wherea
number
cell
nonpaint
cell
p
moreov
gain
cell
number
accompani
reduct
cell
cfse
intens
fig
indic
vivo
prolifer
cell
collect
result
indic
paint
cell
increas
surviv
also
expans
vivo
upon
adopt
transfer
perform
winn
assay
determin
whether
increas
viabil
expans
cell
associ
stronger
antitumor
activ
vivo
end
cell
serial
dilut
mix
fix
number
lymphoma
cell
tumor
line
express
hen
ovalbumin
pseudo
tumor
antigen
specif
recogn
cell
cell
mixtur
inject
intraderm
back
flank
syngen
mice
result
show
per
cell
basi
cell
least
time
potent
nonpaint
control
cell
inhibit
tumor
growth
fig
aggreg
data
suggest
use
cellrestrict
modul
increas
antitumor
efficaci
adopt
therapi
data
exclud
possibl
increas
antitumor
efficaci
cell
may
mediat
mechan
besid
increas
survivalexpans
cell
one
mechan
may
paint
allow
specif
target
antitumor
cell
thu
minim
stimul
regulatori
cell
patient
occur
convent
therapi
expans
endogen
suppress
cell
dampen
antitumor
immun
detriment
cancer
therapi
strategi
may
enhanc
antitumor
efficaci
also
bypass
limit
explor
util
cancer
therapi
next
evalu
antitumor
efficaci
second
modal
inject
situ
directli
tumor
bed
choos
modal
base
upon
reason
other
shown
intratumor
protein
transfer
immunestimulatori
protein
induc
local
tumor
regress
also
longterm
system
antitumor
immun
moreov
particularli
well
suit
local
therapi
intratumor
inject
would
retain
within
tumor
therebi
minim
system
toxic
end
mice
intraderm
inocul
syngen
melanoma
cell
back
flank
day
start
day
mice
bear
palpabl
tumor
inject
intratumor
ng
iu
daili
consecut
day
nontreat
mice
mice
treat
serv
control
shown
fig
mice
surviv
longer
nontreat
p
p
control
mice
consist
result
compar
control
group
mice
fewer
metastat
tumor
p
control
lung
fig
moreov
shown
fig
mice
activ
cell
spleen
nontreat
p
p
control
mice
presenc
activ
cell
spleen
lymphoid
organ
distal
tumor
site
suggest
induct
system
antitumor
immun
notabl
mice
treat
result
activ
cell
compar
nontreat
mice
consist
observ
also
effect
alter
tumor
microenviron
shown
fig
compar
tumor
tumor
time
regulatori
cell
p
time
activ
effector
cell
p
indic
compar
stronger
bia
toward
effector
cell
respons
aggreg
result
suggest
intratumor
inject
prolong
anim
surviv
induc
local
system
antitumor
immun
system
toxic
limit
dose
may
toler
patient
turn
limit
efficaci
drug
henc
ask
whether
less
toxic
may
thu
administ
higher
dose
end
mice
bear
melanoma
given
intratumor
inject
iu
three
time
daili
consecut
day
inject
total
regimen
known
caus
vascular
leakag
syndrom
vl
indic
system
toxic
shown
fig
injectioninduc
vascular
leakag
lung
readili
detect
mice
inject
essenti
absent
mice
inject
p
lack
toxic
latter
group
attribut
weak
biolog
activ
shown
activ
fig
neither
attribut
inactiv
effect
inhibit
tumor
growth
p
fig
consist
stronger
antitumor
effect
shown
fig
b
also
observ
slight
enlarg
spleen
group
fig
contrast
group
show
inhibit
tumor
growth
despit
markedli
enlarg
spleen
p
conclus
gener
new
form
spontan
incorpor
onto
cell
surfac
adopt
cell
transfer
situ
therapi
show
stronger
antitumor
efficaci
furthermor
inject
directli
tumor
tissu
caus
less
toxic
like
local
retent
upon
incorpor
onto
cell
henc
may
potenti
serv
use
altern
therapi
treat
cancer
end
futur
work
need
demonstr
pharmacokinet
altern
form
cytokin
well
pharmacodynam
interact
cell
immun
cell
also
conceiv
approach
establish
may
use
derivat
cytokin
gener
effect
less
toxic
cytokin
drug
cancer
paint
cell
enhanc
surviv
antitumor
efficaci
adopt
transfer
therapi
cell
activ
expand
ex
vivo
day
cell
cell
thoroughli
wash
paint
ng
wash
replat
ml
medium
control
equal
number
nonpaint
cell
replat
ml
medium
neg
control
medium
contain
ng
iu
posit
control
sampl
taken
daili
stain
live
cell
count
flow
cytometri
shown
experi
similar
result
b
cell
label
cfse
cfselabel
cell
paint
mockpaint
nonpaint
nt
subsequ
coinject
equal
number
nonpaint
cell
footpad
three
day
later
surviv
donor
cell
poplit
lymph
node
analyz
flow
cytometri
cell
gate
dot
plot
show
experi
similar
result
bar
graph
show
combin
result
experi
p
p
c
nonpaint
cell
mix
tumor
cell
indic
ratio
subsequ
inject
intraderm
mice
n
growth
tumor
follow
weekli
shown
experi
similar
result
dot
tumor
cell
inject
alon
circl
tumor
cell
inject
cell
situ
therapi
lead
effect
antitumor
respons
melanoma
inocul
day
back
flank
mice
intraderm
inject
melanoma
cell
mous
day
palpabl
tumor
treat
intratumor
inject
ngmous
daili
consecut
day
solid
line
control
group
noninject
dot
line
inject
dash
line
surviv
anim
n
group
follow
daili
shown
experi
similar
result
p
treat
p
nontreat
control
group
mannwhitney
u
test
b
tumorbear
mice
treat
describ
day
number
metastat
coloni
lung
count
dissect
scope
autopsi
perform
time
death
mice
die
day
shown
combin
result
separ
experi
consist
total
mice
treatment
group
p
c
tumorbear
mice
treat
day
spleen
cell
stain
fix
permeabil
stain
intracellular
cell
count
flow
cytometri
percentag
total
cell
shown
combin
result
separ
experi
consist
total
mice
treatment
group
p
p
tumorbear
mice
treat
day
tumor
excis
digest
collagenas
releas
cell
filter
stain
regulatori
egfp
activ
effector
cell
count
flow
cytometri
percentag
total
cell
analysi
latter
cell
fix
permeabil
stain
intracellular
shown
combin
result
separ
experi
consist
total
mice
treatment
group
p
p
p
lower
system
toxic
mice
bear
melanoma
inject
intratumor
iu
time
daili
day
inject
total
mice
inject
pb
use
neg
control
two
hour
last
inject
vl
determin
evan
blue
assay
percent
increas
extravas
calcul
formula
tc
quantiti
dye
lung
given
mous
c
mean
quantiti
dye
lung
pbstreat
mice
p
b
size
tumor
measur
time
